[go: up one dir, main page]

BRPI0812322A2 - Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica - Google Patents

Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica

Info

Publication number
BRPI0812322A2
BRPI0812322A2 BRPI0812322-5A2A BRPI0812322A BRPI0812322A2 BR PI0812322 A2 BRPI0812322 A2 BR PI0812322A2 BR PI0812322 A BRPI0812322 A BR PI0812322A BR PI0812322 A2 BRPI0812322 A2 BR PI0812322A2
Authority
BR
Brazil
Prior art keywords
neutrotoxic
thermostable
provision
component
muscle relaxant
Prior art date
Application number
BRPI0812322-5A2A
Other languages
English (en)
Inventor
Karl Heinz Eisele
Matthias Marx
Harold V Taylor
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07010912A external-priority patent/EP1997509A1/en
Priority claimed from EP07020025A external-priority patent/EP2048156A1/en
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BRPI0812322A2 publication Critical patent/BRPI0812322A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0812322-5A2A 2007-06-01 2008-05-28 Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica BRPI0812322A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93262407P 2007-06-01 2007-06-01
EP07010912A EP1997509A1 (en) 2007-06-01 2007-06-01 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
US99885807P 2007-10-12 2007-10-12
EP07020025A EP2048156A1 (en) 2007-10-12 2007-10-12 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
PCT/EP2008/004254 WO2008145359A1 (en) 2007-06-01 2008-05-28 Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin

Publications (1)

Publication Number Publication Date
BRPI0812322A2 true BRPI0812322A2 (pt) 2014-11-25

Family

ID=40074591

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0812245-8A2A BRPI0812245A2 (pt) 2007-06-01 2008-05-28 Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica na forma sólida
BRPI0812322-5A2A BRPI0812322A2 (pt) 2007-06-01 2008-05-28 Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0812245-8A2A BRPI0812245A2 (pt) 2007-06-01 2008-05-28 Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica na forma sólida

Country Status (15)

Country Link
US (2) US20090028906A1 (pt)
EP (2) EP2170375A1 (pt)
JP (2) JP2010529000A (pt)
KR (2) KR20100020972A (pt)
CN (2) CN101720331A (pt)
AR (2) AR066782A1 (pt)
AU (2) AU2008256419A1 (pt)
BR (2) BRPI0812245A2 (pt)
CA (2) CA2686637A1 (pt)
IL (2) IL202130A0 (pt)
MX (2) MX2009012990A (pt)
RU (1) RU2009149604A (pt)
TW (2) TW200902050A (pt)
WO (2) WO2008145358A1 (pt)
ZA (2) ZA200907874B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
LT2379104T (lt) 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
MX340772B (es) * 2009-02-19 2016-07-26 Merz Pharma Gmbh & Co Kgaa Medios y metodos para fabricar neurotoxina altamente pura.
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
CA2757637C (en) * 2009-04-27 2017-10-24 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
BRPI1015938A2 (pt) 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
PL2490986T3 (pl) * 2009-10-21 2019-03-29 Revance Therapeutics, Inc. Sposoby i systemy oczyszczania nieskompleksowanej neurotoksyny botulinowej
DK2692350T4 (da) * 2011-03-31 2023-09-04 Medy Tox Inc Lyofiliseret præparat af botulinumtoksin
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
EP3590500B1 (en) * 2014-12-23 2025-06-25 Merz Pharma GmbH & Co. KGaA Botulinum toxin prefilled container
JP6813492B2 (ja) 2015-02-03 2021-01-13 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素充填済み容器
EP3070539A1 (fr) * 2015-03-17 2016-09-21 Omega SA Montre-bracelet comprenant un cadran muni d'index lumineux
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
WO2020138674A1 (ko) 2018-12-26 2020-07-02 (주)케어젠 근육 이완용 조성물
MX2020014330A (es) * 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
TWI852454B (zh) * 2022-04-01 2024-08-11 大陸商重慶譽顏製藥有限公司 一種肉毒毒素蛋白組合物、製備方法及其應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20030224020A1 (en) * 2002-05-31 2003-12-04 Zabudkin Alexander F. Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
CA2578250C (en) * 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
HRP20090382T1 (hr) 2005-06-17 2009-09-30 Merz Pharma Gmbh & Co.Kgaa Uređaj i postupak za proizvodnju biološko aktivnih spojeva fermentacijom
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica

Also Published As

Publication number Publication date
IL202129A0 (en) 2010-06-16
IL202130A0 (en) 2010-06-16
EP2170375A1 (en) 2010-04-07
ZA200907875B (en) 2010-11-24
WO2008145359A1 (en) 2008-12-04
WO2008145358A1 (en) 2008-12-04
ZA200907874B (en) 2011-03-30
CN101687018A (zh) 2010-03-31
CN101720331A (zh) 2010-06-02
BRPI0812245A2 (pt) 2014-10-21
EP2164861A1 (en) 2010-03-24
US20090028906A1 (en) 2009-01-29
US20090010965A1 (en) 2009-01-08
AR066782A1 (es) 2009-09-09
CA2686637A1 (en) 2008-12-04
TW200914039A (en) 2009-04-01
AU2008256419A1 (en) 2008-12-04
TW200902050A (en) 2009-01-16
JP2010528999A (ja) 2010-08-26
MX2009012570A (es) 2010-03-15
AU2008256418A1 (en) 2008-12-04
RU2009149604A (ru) 2011-07-20
KR20100020971A (ko) 2010-02-23
JP2010529000A (ja) 2010-08-26
MX2009012990A (es) 2010-04-01
AR066783A1 (es) 2009-09-09
CA2686642A1 (en) 2008-12-04
KR20100020972A (ko) 2010-02-23

Similar Documents

Publication Publication Date Title
BRPI0812322A2 (pt) Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica
BRPI0821729A2 (pt) Tapete, revestimento de tapete e método para fabricar um tapete
BRPI0811830A2 (pt) "composição de revestimento, método para revestir um substrato e substrato"
BRPI0720235A2 (pt) Método para produzir um item de vestuário, e, item de vestuário
BRPI0819891A2 (pt) aparelho modular de poço para determinar uma propriedade da formação, e método para determinar um propriedade da formação
BRPI0817398A2 (pt) "método para fabricação de um dispositivo, dispositivo para inalação e dispositivo ou componente"
BRPI0920301A2 (pt) método para marcar um substrato oftálmico ou outro artigo oftálmico, e, aparelho
BRPI0807906A2 (pt) Token pessoal tendo habilidades de comunicação aperfeiçoadas para um aplicativo hospedado.
EP2024026A4 (en) NERVE COIFFE AND METHOD AND APPARATUS FOR MANUFACTURING THE SAME
FI20065404L (fi) Prosessi perusöljyn valmistamiseksi
DK2046831T3 (da) Hidtil ukendte, multivalente immunoglobuliner
BRPI0717412A2 (pt) Filme único, e, método para a produção de um filme único
BRPI0715287A2 (pt) "método de avaliação do progresso de cicatrização de feridas"
EP2136626A4 (en) Mannich base n-oxide drugs
EP2035398A4 (en) Immobilized 1,2-benzisothiazolin-3-one
BRPI0908689A2 (pt) 'método para formação de uma sinalização, sinalizações e métodos para formação de um artigo com imagem
DE102007031935B8 (de) Bauteil mit funktionellen Elementen sowie Verfahren zu dessen Herstellung
DE602007010225D1 (de) Synchronisationsverfahren und -anordnung
AT506023A3 (de) Elastischer walzenüberzug, überzogene walze und verfahren zur herstellung einer überzogenen walze
BRPI0917952A2 (pt) método para fabricaar um componente de revestimento para um moinho, e, componente de revistimento para um moinho
BRPI0718200A2 (pt) aparelho para observar a aparência da superfície de uma amostra, e, método para observar a aparência da superfície de uma amostra
BRPI0813366A2 (pt) Método para executar uma combustão.
DE502007002958D1 (de) Armierte supraleitende wicklung und verfahren zu deren herstellung
DE112007003218A5 (de) Antihaftbeschichtung
FR2919402B1 (fr) Procede de test d'une application logicielle.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 38/48 (2006.01)